PNC Financial Services Group Inc. Reduces Position in Abbott Laboratories $ABT

PNC Financial Services Group Inc. decreased its holdings in Abbott Laboratories (NYSE:ABT) by 0.3% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 4,580,444 shares of the healthcare product maker’s stock after selling 11,966 shares during the period. PNC Financial Services Group Inc. owned about 0.26% of Abbott Laboratories worth $613,505,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently bought and sold shares of ABT. Vanguard Group Inc. grew its stake in Abbott Laboratories by 1.8% during the 2nd quarter. Vanguard Group Inc. now owns 172,800,851 shares of the healthcare product maker’s stock worth $23,502,644,000 after buying an additional 2,977,715 shares during the last quarter. State Street Corp boosted its holdings in Abbott Laboratories by 0.9% in the second quarter. State Street Corp now owns 78,354,270 shares of the healthcare product maker’s stock worth $10,656,964,000 after acquiring an additional 689,517 shares in the last quarter. Geode Capital Management LLC grew its stake in shares of Abbott Laboratories by 3.8% during the second quarter. Geode Capital Management LLC now owns 38,293,067 shares of the healthcare product maker’s stock worth $5,184,589,000 after acquiring an additional 1,390,554 shares during the last quarter. Norges Bank acquired a new stake in shares of Abbott Laboratories during the second quarter worth $3,026,180,000. Finally, Massachusetts Financial Services Co. MA increased its position in shares of Abbott Laboratories by 5.8% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 15,096,907 shares of the healthcare product maker’s stock valued at $2,022,080,000 after acquiring an additional 821,325 shares during the period. 75.18% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, Director Daniel J. Starks purchased 10,000 shares of the business’s stock in a transaction on Wednesday, February 4th. The shares were bought at an average price of $108.73 per share, for a total transaction of $1,087,300.00. Following the acquisition, the director directly owned 6,738,817 shares in the company, valued at $732,711,572.41. This trade represents a 0.15% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.46% of the stock is owned by insiders.

Abbott Laboratories Stock Up 1.0%

Shares of NYSE ABT opened at $112.63 on Friday. Abbott Laboratories has a 52-week low of $105.27 and a 52-week high of $141.23. The firm has a market cap of $195.84 billion, a price-to-earnings ratio of 30.28, a price-to-earnings-growth ratio of 1.79 and a beta of 0.75. The company has a quick ratio of 1.24, a current ratio of 1.70 and a debt-to-equity ratio of 0.23. The company’s 50-day simple moving average is $119.48 and its 200-day simple moving average is $126.40.

Abbott Laboratories (NYSE:ABT) last released its earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share for the quarter, hitting analysts’ consensus estimates of $1.50. Abbott Laboratories had a net margin of 14.72% and a return on equity of 17.94%. The business had revenue of $11.46 billion for the quarter, compared to analyst estimates of $11.80 billion. During the same period last year, the company posted $1.34 EPS. The business’s revenue was up 4.4% on a year-over-year basis. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. Equities analysts predict that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Abbott Laboratories Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, February 13th. Shareholders of record on Thursday, January 15th were paid a $0.63 dividend. This represents a $2.52 annualized dividend and a dividend yield of 2.2%. This is a positive change from Abbott Laboratories’s previous quarterly dividend of $0.59. The ex-dividend date was Thursday, January 15th. Abbott Laboratories’s payout ratio is presently 67.74%.

Analysts Set New Price Targets

Several research firms have weighed in on ABT. Citigroup dropped their price target on Abbott Laboratories from $155.00 to $140.00 and set a “buy” rating on the stock in a research note on Friday, January 23rd. Leerink Partners dropped their price objective on shares of Abbott Laboratories from $136.00 to $119.00 and set a “market perform” rating on the stock in a report on Friday, January 30th. Royal Bank Of Canada reduced their target price on shares of Abbott Laboratories from $147.00 to $135.00 and set an “outperform” rating for the company in a report on Friday, January 23rd. Freedom Capital raised shares of Abbott Laboratories from a “hold” rating to a “strong-buy” rating in a report on Thursday, January 29th. Finally, Barclays reduced their price objective on Abbott Laboratories from $169.00 to $142.00 and set an “overweight” rating for the company in a research note on Monday, February 2nd. Two research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat, Abbott Laboratories presently has a consensus rating of “Moderate Buy” and a consensus price target of $137.05.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.